WO2007093020A1 - Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. - Google Patents

Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. Download PDF

Info

Publication number
WO2007093020A1
WO2007093020A1 PCT/BR2006/000028 BR2006000028W WO2007093020A1 WO 2007093020 A1 WO2007093020 A1 WO 2007093020A1 BR 2006000028 W BR2006000028 W BR 2006000028W WO 2007093020 A1 WO2007093020 A1 WO 2007093020A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
treatment
platelet aggregation
hypertension
package
Prior art date
Application number
PCT/BR2006/000028
Other languages
French (fr)
Inventor
Moreira De Almeida Igor
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to PCT/BR2006/000028 priority Critical patent/WO2007093020A1/en
Publication of WO2007093020A1 publication Critical patent/WO2007093020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Definitions

  • the present invention is presented under package or drug kit form or oral treatment presentation for treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.
  • Blood pressure control is important to reduce risks and/or to prevent cardiovascular diseases, such as angina, myocardial infarction, among others.
  • Packaging system is just known.
  • Document US 2002/0045184 is related to a drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug, wherein said first drug and second drug are independently selected from a group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methy!glutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.
  • ACE angiotensin converting enzyme
  • HMG CoA 3-hydroxy-3-methy!glutaryl coenzyme A
  • the invention comprises a nonsteroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor.
  • a proton pump inhibitor it is possible to select a drug from the group consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, isomers, enantiomers or pharmaceutically acceptable salts thereof, preferably omeprazole.
  • non-steroidal anti-inflammatory drug it is possible to select a drug from the group consisting of: naproxen, diclofenac, sulindac, oxaprozin, diflunisal, aspirin, piroxicam, indomethacin, etodolac, ibuprofen, fenoprofen, ketoprofen, mefenamic acid, nabumetone, tolmetin, ketorolac, preferably diclofenac.
  • Document US 6273260 describes a packaging system for storing and dispering individual doses of medication on prescribed days wherein the individual dose of medication is an enteric fluoxetine pellet comprising: a) a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients; d) an optional finishing layer.
  • HPMCAS hydroxypropylmethylcellulose acetate succinate
  • Document BR 9609559 describes a packaging system for storing pills that are administered in a gradually increasing dosage during the period of treatment.
  • Document BR MU8302502 deals about a packaging system or kit of medicaments for the treatment of arteriosclerotic disease, comprising one or more anti-thrombocyte agents, that may be: simvastatin, atorvastatin, pravastatin, lovastatin, fluvastatin and rosuvastatin, preferentially the simvastatin and one or more agents, capable to meliorate the lipid profile of blood, like the acetyl salicylic acid, or ticlopidine, preferentially the acetylsalicylic acid.
  • anti-thrombocyte agents that may be: simvastatin, atorvastatin, pravastatin, lovastatin, fluvastatin and rosuvastatin, preferentially the simvastatin and one or more agents, capable to meliorate the lipid profile of blood, like the acetyl salicylic acid, or ticlopidine, preferentially the acetylsal
  • Document BR MU8201733 deals about a packaging system or kit of medicaments, particularly for treating ulcerous gastro-intestinal problems, caused by the bacterium Helicobacter pylori, presenting one or more antibiotics like amoxicillin, erythromycin, metronidazole, tinidazole, preferentially amoxicillin and erythromycin and one or more inhibitors of the proton pump (IBP), like the lansoprazole, omeprazole, pantoprazole, rabeprazole, esomeprazole, preferentially the lansoprazole.
  • IBP proton pump
  • This invention is a matter of package, or drug kit, or drug smooth administering presentation for the treatment of hypertension, coronary disease chest pain and decrease platelet aggregation.
  • This invention describes a packaging system, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of a platelet aggregation inhibitor agent and one or more unit dosage forms of a calcium antagonist agent, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information.
  • the mentioned invention provides easiness on the combination use of one antihypertensive drug and one platelet aggregation inhibitor drug, through its administration form that shows an additional benefit compared to the simple treatment.
  • the invention's objectives are: a) to emphasize the importance of the administration of both drugs together; b) to enhance treatment adhesion; c) to guarantee that both drugs are taken.
  • the outer carton, blister or similar brings written information that facilitates the patient's adhesion and the drug/product handle.
  • the outer carton, blister or similar contains two products: one anti-hypertensive of calcium antagonists, plain class and another one of platelet aggregation inhibitor class. First one is indicated for hypertension treatment, coronary disease and stable angina and the second to inhibit platelet aggregation in: instable angina, heart attack and others.
  • the presentation aims at the functionality relating to one already available in the market.
  • the mentioned drugs are already known in the market and are available in blisters, outer cartons or similar; however, they are commercialized on an independent way. It was developed a package or drug kit or drug smooth administration presentation of both drugs.
  • the product has didactic, safe and clear information that facilitates use and handling of the drugs.
  • Both of the drugs have, together, the whole of treating hypertension, cardiovascular diseases and decrease platelet aggregation.
  • the active principles that aim reducing or adjusting blood pressure comprising calcium antagonists, plain class may be selected from the group comprising: amlodipine, nifedipine, verapamil, felodipine, nitrendipine, isradipine, nisoldipine, diltiazem, mibefradil, manidipine, lacidipine and lercandipine, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
  • Unit dosage may vary from 10 mg to 1000 mg, optionally associated with others drugs, following medical orientation, preferably 20 mg, or 30 mg, or 60 mg per tablet unit.
  • the active principles that aim at inhibiting platelet aggregation in instable angina, heart attack and others may be selected from the group comprising: cilostazol, ticlopidine, acetylsalicylic acid, triflusal, dipyridamole, clopidrogel, abciximab, tirofiban, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
  • Unit dosages may vary from 10 mg until 1000 mg, optionally associated with others drugs, following medical orientation, preferably 100 mg, or 200 mg, or 300 mg per tablet unit.
  • the active principles can be presented under tablets, coated tablet, capsules, soft gel capsules, or any other pharmaceutically or galenic forms known by the man skilled in the art.
  • Said platelet aggregation inhibitor agent and / or calcium antagonist agent may be mixtures or associated with other synergic actives, like diuretics or others antihypertensives.
  • Package may comprise 28 or 14 or 7 tablets of a platelet aggregation inhibitor agents and 28 or 14 or 7 tablets of calcium antagonist agent, or any other amount suitable for the treatment period.
  • the invention is a packaging system, or a drug kit or a smooth administration presentation of both drugs in outer carton, blister or similar with one or more units of acetylsalicylic acid and one or more units of nifedipine, optionally associated with others drugs, with clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken and periodicity of the treatment.
  • the invention is a package, or a drug kit or a smooth administration presentation with 28 or 14 or 7 tablets of each active principle, or others amounts suitable for the treatment, with unit dosages for 10 mg to 1000 mg of each tablet or each active, acetylsalicylic acid or nifedipine, or others synergic drugs. Dosages of each unit respects medical orientation and are supported by clinical trials which validate the concomitant use of these products following the mentioned dosages.
  • the suggested administration is one tablet of each active principle per day or under medical orientation, during the period established by the doctor or health professional.
  • the invention includes in each outer carton, blister or similar there are a dosage unit of nifedipine and a dosage unit acetylsalicylic acid, optionally associated with others drugs, presented under a clear and didactic way, which contains written technical and informative orientation about active principle, dosage, recommended dosage, day of week, period and periodicity. It may comprise 28 or 14 or 7 tablets of acetylsalicylic acid and 28 or 14 or 7 tablets of nifedipine for the treatment period, or any other amount suitable for the treatment.
  • Acetylsalicylic acid unit dosage is 100 mg, or 200 mg, or 300 mg and nifedipine unit dosage is 20 mg, or 30 mg, or 60 mg.
  • Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation is indicated for instable angina, heart attack and others kinds of diseases.
  • the following example aims at illustrating the invention or package, or drug kit or smooth administration presentation; however, it should not restrict the model draft.
  • FIGURE 1 attached, elucidates one of the outer carton of the package, according to the invention, as follow:
  • the figure represents the outer carton, containing units of medicines, according to the TABLE 1 , below:

Abstract

This invention refers to a packaging system, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of a platelet aggregation inhibitor agent and one or more unit dosage forms of a calcium antagonist agent, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information, as indicated in FIGURE 1. The invention is destined to a treatment presentation for hypertension, cardiovascular diseases and decrease platelet aggregation. Blood pressure control is important to reduce risks and/or to prevent cardiovascular diseases, such as angina, myocardial infarction, among others.

Description

PACKAGE, OR DRUG KIT, OR DRUG SMOOTH ADMINISTRATION PRESENTATION FOR THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISEASES AND DECREASE PLATELET AGGREGATION.
The present invention is presented under package or drug kit form or oral treatment presentation for treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. Blood pressure control is important to reduce risks and/or to prevent cardiovascular diseases, such as angina, myocardial infarction, among others.
The types of packing or orientation kit for patients suffering from chronic dysfunctions and whose treatment involves administering of various types of active ingredients to be ingested in different quantities and at different times of the day, during the period of long-lasting treatment, had a quite facilitating effect, thus increasing the chances of continuation and termination of the treatment by the patient himself and the consequent success of same. Some types of packing or kit with such purpose have already been known, however, they are of a very specific character for each type of disease to be treated, because they are reproducing in a didactical and facilitating way for the patient, a method of medium term treatment.
Packaging system is just known. Document US 2002/0045184 is related to a drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug, wherein said first drug and second drug are independently selected from a group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methy!glutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics. Particularly, the invention comprises a nonsteroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor. As a proton pump inhibitor it is possible to select a drug from the group consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, isomers, enantiomers or pharmaceutically acceptable salts thereof, preferably omeprazole. As a non-steroidal anti-inflammatory drug it is possible to select a drug from the group consisting of: naproxen, diclofenac, sulindac, oxaprozin, diflunisal, aspirin, piroxicam, indomethacin, etodolac, ibuprofen, fenoprofen, ketoprofen, mefenamic acid, nabumetone, tolmetin, ketorolac, preferably diclofenac.
Document US 6273260 describes a packaging system for storing and dispering individual doses of medication on prescribed days wherein the individual dose of medication is an enteric fluoxetine pellet comprising: a) a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients; d) an optional finishing layer.
Document BR 9609559 describes a packaging system for storing pills that are administered in a gradually increasing dosage during the period of treatment.
Document BR MU8302502 deals about a packaging system or kit of medicaments for the treatment of arteriosclerotic disease, comprising one or more anti-thrombocyte agents, that may be: simvastatin, atorvastatin, pravastatin, lovastatin, fluvastatin and rosuvastatin, preferentially the simvastatin and one or more agents, capable to meliorate the lipid profile of blood, like the acetyl salicylic acid, or ticlopidine, preferentially the acetylsalicylic acid.
Document BR MU8201733 deals about a packaging system or kit of medicaments, particularly for treating ulcerous gastro-intestinal problems, caused by the bacterium Helicobacter pylori, presenting one or more antibiotics like amoxicillin, erythromycin, metronidazole, tinidazole, preferentially amoxicillin and erythromycin and one or more inhibitors of the proton pump (IBP), like the lansoprazole, omeprazole, pantoprazole, rabeprazole, esomeprazole, preferentially the lansoprazole.
This invention is a matter of package, or drug kit, or drug smooth administering presentation for the treatment of hypertension, coronary disease chest pain and decrease platelet aggregation.
The regular use of drugs to control blood pressure helps to prevent cardiovascular diseases development and to improve patient's life quality. In patients with high blood pressure and coronary disease chest pain is recommended to take anti-hypertensive drugs and platelet aggregation inhibitor. This invention describes a packaging system, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of a platelet aggregation inhibitor agent and one or more unit dosage forms of a calcium antagonist agent, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information.
The mentioned invention provides easiness on the combination use of one antihypertensive drug and one platelet aggregation inhibitor drug, through its administration form that shows an additional benefit compared to the simple treatment. Hence, the invention's objectives are: a) to emphasize the importance of the administration of both drugs together; b) to enhance treatment adhesion; c) to guarantee that both drugs are taken.
The outer carton, blister or similar brings written information that facilitates the patient's adhesion and the drug/product handle. The outer carton, blister or similar contains two products: one anti-hypertensive of calcium antagonists, plain class and another one of platelet aggregation inhibitor class. First one is indicated for hypertension treatment, coronary disease and stable angina and the second to inhibit platelet aggregation in: instable angina, heart attack and others. The presentation aims at the functionality relating to one already available in the market.
The mentioned drugs are already known in the market and are available in blisters, outer cartons or similar; however, they are commercialized on an independent way. It was developed a package or drug kit or drug smooth administration presentation of both drugs. The product has didactic, safe and clear information that facilitates use and handling of the drugs.
Both of the drugs have, together, the whole of treating hypertension, cardiovascular diseases and decrease platelet aggregation.
The active principles that aim reducing or adjusting blood pressure comprising calcium antagonists, plain class, may be selected from the group comprising: amlodipine, nifedipine, verapamil, felodipine, nitrendipine, isradipine, nisoldipine, diltiazem, mibefradil, manidipine, lacidipine and lercandipine, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof. Unit dosage may vary from 10 mg to 1000 mg, optionally associated with others drugs, following medical orientation, preferably 20 mg, or 30 mg, or 60 mg per tablet unit. The active principles that aim at inhibiting platelet aggregation in instable angina, heart attack and others, may be selected from the group comprising: cilostazol, ticlopidine, acetylsalicylic acid, triflusal, dipyridamole, clopidrogel, abciximab, tirofiban, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof. Unit dosages may vary from 10 mg until 1000 mg, optionally associated with others drugs, following medical orientation, preferably 100 mg, or 200 mg, or 300 mg per tablet unit.
The active principles can be presented under tablets, coated tablet, capsules, soft gel capsules, or any other pharmaceutically or galenic forms known by the man skilled in the art. Said platelet aggregation inhibitor agent and / or calcium antagonist agent may be mixtures or associated with other synergic actives, like diuretics or others antihypertensives.
Package may comprise 28 or 14 or 7 tablets of a platelet aggregation inhibitor agents and 28 or 14 or 7 tablets of calcium antagonist agent, or any other amount suitable for the treatment period.
The invention is a packaging system, or a drug kit or a smooth administration presentation of both drugs in outer carton, blister or similar with one or more units of acetylsalicylic acid and one or more units of nifedipine, optionally associated with others drugs, with clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken and periodicity of the treatment. The invention is a package, or a drug kit or a smooth administration presentation with 28 or 14 or 7 tablets of each active principle, or others amounts suitable for the treatment, with unit dosages for 10 mg to 1000 mg of each tablet or each active, acetylsalicylic acid or nifedipine, or others synergic drugs. Dosages of each unit respects medical orientation and are supported by clinical trials which validate the concomitant use of these products following the mentioned dosages.
The suggested administration is one tablet of each active principle per day or under medical orientation, during the period established by the doctor or health professional. In a particular way of realization, the invention includes in each outer carton, blister or similar there are a dosage unit of nifedipine and a dosage unit acetylsalicylic acid, optionally associated with others drugs, presented under a clear and didactic way, which contains written technical and informative orientation about active principle, dosage, recommended dosage, day of week, period and periodicity. It may comprise 28 or 14 or 7 tablets of acetylsalicylic acid and 28 or 14 or 7 tablets of nifedipine for the treatment period, or any other amount suitable for the treatment. Acetylsalicylic acid unit dosage is 100 mg, or 200 mg, or 300 mg and nifedipine unit dosage is 20 mg, or 30 mg, or 60 mg.
Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation is indicated for instable angina, heart attack and others kinds of diseases. The following example aims at illustrating the invention or package, or drug kit or smooth administration presentation; however, it should not restrict the model draft.
Example 1 :
The FIGURE 1, attached, elucidates one of the outer carton of the package, according to the invention, as follow:
(1 ) Brand name of the product;
(2) Active principles names: nifedipine and acetylsalicylic acid, indication of the dosage and also optionally indication of the pharmaceutical form of the active, for example: enteric coated, CITS, etc; (3) Indication for the daily dosage. The outer carton contains 7 dosages, indicating one dosage per day;
The figure represents the outer carton, containing units of medicines, according to the TABLE 1 , below:
Acetylsalicylic acid tablets Nifedipine tablets quantity Days of treatment quantity and dosage and dosage
1 unit 1 unit
Monday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
1 unit 1 unit
Tuesday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg) 1 unit 1 unit
Wednesday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
1 unit 1 unit
Thursday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
1 unit 1 unit
Friday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
1 unit 1 unit
Saturday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
1 unit 1 unit
Sunday
(100 mg or 200 mg or 300 mg) (20 mg or 30 mg or 60 mg)
TABLE 1

Claims

1. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of a platelet aggregation inhibitor agent and one or more unit dosage forms of a calcium antagonist agent, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information.
2. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, according to claim 1 , wherein platelet aggregation inhibitor agents may be selected from the group comprising: cilostazol, ticlopidine, acetylsalicylic acid, triflusal, dipyridamole, clopidrogel, abciximab and tirofiban, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
3. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, according to claims 1 or 2, wherein agent of platelet aggregation inhibitor is acetylsalicylic acid in any pharmaceutically or galenic forms.
4. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 or 2, wherein said platelet aggregation inhibitor unit dosage for 10 mg until 1000 mg.
5. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 4, wherein said platelet aggregation inhibitor unit dosage for 100 mg or 200 mg or 300 mg.
6. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 3, wherein said acetylsalicylic acid is enteric coated.
7. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 , wherein said calcium antagonist agent is selected from the group consisting of: amlodipine, nifedipine, verapamil, felodipine, nitrendipine, isradipine, nisoldipine, diltiazem, mibefradil, manidipine, lacidipine and lercandipine, or its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
8. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 or 7, wherein said calcium antagonist agent is nifedipine.
9. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 or 7, wherein said calcium antagonist agent unit dosage for 10 mg until 1000 mg.
10. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 9 wherein calcium antagonist agent unit dosage is 20 mg, or 30 mg, or 60 mg.
11. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 wherein said platelet aggregation inhibitor agent and / or calcium antagonist agent may be mixtures or associated with other synergic actives, like diuretics or others anti-hypertensives.
12. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 comprising 28 or 14 or 7 tablets of a platelet aggregation inhibitor agents and 28 or 14 or 7 tablets of calcium antagonist agent, or any other amount suitable for the treatment period.
13. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 , wherein the drug unites presented in outer 'carton, blister or similar feature: tablets, coated tablet, capsules, soft gel capsules, or any other pharmaceutical form known by the man skilled in the art.
14. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of acetylsalicylic acid or its pharmaceutically acceptable salts and one or more unit dosage forms of nifedipine or its pharmaceutically acceptable salts, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information.
15. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 12, wherein unit dosage forms of actives are daily, being taking: one or more dosage units of acetylsalicylic acid for 10 mg until 1000 mg and one one or more dosage units of nifedipine for 10 mg until 1000 mg.
16. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 12, wherein unit dosage forms of actives are daily, being taking: one or more dosage units of acetylsalicylic acid 100 mg, or 200 mg, or 300 mg.
17. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 12, wherein unit dosage forms of actives are daily, being taking: one or more dosage units of nifedipine 20 mg, or 30 mg, or 60 mg.
18. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 1 for a treatment period of 28 or 14 or 7 days or a different periodicity suitable for the treatment, or under medical orientation.
19. Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation according to claim 13, wherein package or drug kit comprise 28 or 14 or 7 tablets of acetylsalicylic acid and 28 or 14 or 7 tablets of nifedipine, or any other amount suitable for the treatment.
PCT/BR2006/000028 2006-02-17 2006-02-17 Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. WO2007093020A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2006/000028 WO2007093020A1 (en) 2006-02-17 2006-02-17 Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2006/000028 WO2007093020A1 (en) 2006-02-17 2006-02-17 Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.

Publications (1)

Publication Number Publication Date
WO2007093020A1 true WO2007093020A1 (en) 2007-08-23

Family

ID=37001089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2006/000028 WO2007093020A1 (en) 2006-02-17 2006-02-17 Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.

Country Status (1)

Country Link
WO (1) WO2007093020A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010020147A1 (en) * 2000-02-28 2001-09-06 John Staniforth Delivery of oral drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010020147A1 (en) * 2000-02-28 2001-09-06 John Staniforth Delivery of oral drugs

Similar Documents

Publication Publication Date Title
US20020045184A1 (en) Packaging system
JP2004500967A (en) Pharmaceutical product package for eradication treatment
JP5986169B2 (en) Oral pharmaceutical combination bound by packaging material
RU96112139A (en) PHARMACEUTICAL DRUG FOR ORAL RECEPTION
US20050284792A1 (en) Pharmaceutical kit for migraine headache treatment
US20050281868A1 (en) Transdermal delivery system for statin combination therapy
DE69940673D1 (en) ORAL SYSTEM FOR THE ADMINISTRATION OF PULSED DOSES OF A MEDICAMENT
TW201306825A (en) Package for improved treatment of conditions
WO2006020522A2 (en) Multiplex drug delivery device
TW201231043A (en) Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor
KR930009605A (en) Anti-inflammatory or analgesic
US20070003490A1 (en) Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against NSAID gastropathy
US20180153866A1 (en) Treatment of sunburn using analgesics and antihistamines
WO2004004776A1 (en) Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
WO2001037831A1 (en) PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND FIBRIC ACID DERIVATIVE
RU2491070C2 (en) Pharmaceutical composition for preventing and treating cardiovascular diseases
WO2007093020A1 (en) Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.
EP1119501B1 (en) A device for organizing the combined use of topical aerosols and oral medication
WO2007093021A1 (en) Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, angina and others kinds of cardiovascular diseases.
ES2811904T3 (en) Pharmaceutical composition comprising bisoprolol and perindopril
NZ521631A (en) Drug combination for the treatment of headache comprising a non-steroidal anti-inflammatory drug
JP2007508242A5 (en)
US20140155435A1 (en) Kit for Treatment of Upper Gastrointestinal Tract Conditions
US20050043359A1 (en) Kit for treatment of upper gastrointestinal tract conditions
FR2926723A1 (en) Oral pharmaceutical dosage form e.g. for treatment of hypercholesterolemia, comprises medicaments brought together in water-soluble wrapping and separated so that active principles in combined medicaments do not contact with one another

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06721588

Country of ref document: EP

Kind code of ref document: A1